IPSEY Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 апр. 2024 @ 21:11):

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases...

Stats
Объем за сегодня	479.00
Средний объем	1 524.00
Рыночная капитализация	9.94B
Last Dividend	$0.324 ( 2023-06-02 )
Next Dividend	$0 ( N/A )
P/E	14.96
ATR14	$0 (0.00%)

Ipsen S.A. Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Ipsen S.A. Финансовые показатели

Annual	2023
Выручка:	$3.13B
Валовая прибыль:	$2.35B (75.10 %)
EPS:	$7.79

FY	2023
Выручка:	$3.13B
Валовая прибыль:	$2.35B (75.10 %)
EPS:	$7.79

FY	2022
Выручка:	$3.16B
Валовая прибыль:	$2.63B (83.28 %)
EPS:	$1.970

FY	2021
Выручка:	$3.00B
Валовая прибыль:	$2.46B (82.06 %)
EPS:	$1.948

Financial Reports:

No articles found.

Ipsen S.A. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0.324 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Ipsen S.A. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.15 - Stable (22.93%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.262	2013-06-11
Last Dividend	$0.324	2023-06-02
Next Dividend	$0	N/A
Payout Date	2023-06-27
Next Payout Date	N/A
# dividends	11	--
Total Paid Out	$3.05	--
Avg. Dividend % Per Year	0.00%	--
Score	3.56	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.15
Div. Directional Score	9.82	--

Next Divdend (Est)
(2025-03-31)

$0.339 Estimate 3.11 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.56

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
TSGTY	Ex Dividend Knight	2023-06-23	Annually	0.00%
JDVB	Ex Dividend Knight	2023-07-27	Quarterly	0.00%
BMBN	Ex Dividend Knight	2023-06-30	Semi-Annually	0.00%
RCBC	Ex Dividend Junior	2023-07-31	Quarterly	0.00%
FABP	Ex Dividend Knight	2023-07-31	Quarterly	0.00%
VNORP	Ex Dividend Knight	2023-09-14	Quarterly	0.00%
LGRDY	Ex Dividend Junior	2023-05-31	Annually	0.00%
CIBN	Ex Dividend Knight	2023-09-14	Quarterly	0.00%
SEBC	Ex Dividend Junior	2023-08-30	Quarterly	0.00%
GBOOY	Ex Dividend Knight	2023-06-15	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.206	1.500	5.88	8.82	[0 - 0.5]
returnOnAssetsTTM	0.102	1.200	6.60	7.92	[0 - 0.3]
returnOnEquityTTM	0.178	1.500	9.13	10.00	[0.1 - 1]
payoutRatioTTM	0.155	-1.000	8.45	-8.45	[0 - 1]
currentRatioTTM	1.167	0.800	9.17	7.33	[1 - 3]
quickRatioTTM	0.864	0.800	9.63	7.70	[0.8 - 2.5]
cashRatioTTM	0.325	1.500	9.31	10.00	[0.2 - 2]
debtRatioTTM	0.0626	-1.500	8.96	-10.00	[0 - 0.6]
interestCoverageTTM	37.44	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	10.20	2.00	6.60	10.00	[0 - 30]
freeCashFlowPerShareTTM	7.99	2.00	6.00	10.00	[0 - 20]
debtEquityRatioTTM	0.103	-1.500	9.59	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.817	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.314	1.000	5.73	5.73	[0.1 - 0.6]
cashFlowToDebtRatioTTM	2.13	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.495	0.800	-0.0358	-0.0286	[0.5 - 2]
Total Score				13.49

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	3.63	1.000	9.73	0	[1 - 100]
returnOnEquityTTM	0.178	2.50	9.44	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	7.99	2.00	7.34	10.00	[0 - 30]
dividendYielPercentageTTM	1.145	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	10.20	2.00	6.60	10.00	[0 - 30]
payoutRatioTTM	0.155	1.500	8.45	-8.45	[0 - 1]
pegRatioTTM	0.0973	1.500	-2.68	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.270	1.000	5.76	0	[0.1 - 0.5]
Total Score				6.15

Ipsen S.A.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.